BioNTech, biotechnology company, and Medigene, a clinical-stage immuno-oncology company, agreed to form a joint venture. Financial terms were not disclosed. “This collaboration with Medigene expands our cell therapy portfolio and TCR discovery capabilities, and further strengthens our ability to be a leader in the rapidly emerging field of engineered cell therapies. We look forward to working closely with Medigene to develop new treatments which address solid tumors with high unmet medical need,” Ugur Sahin, BioNTech CEO and Co-Founder.